Sandoz to Pay $450 Million to Settle U.S. Generic Drug Probe, Reaffirms Guidance

Sandoz Group AG (SIX:SDZ) has agreed to a $450 million settlement to resolve a multi-state U.S. investigation into alleged anti-competitive practices in the generic pharmaceuticals market. The Swiss drugmaker confirmed on Monday that the agreement will not impact its current financial guidance, removing a significant legal uncertainty for the company.

Settlement Details

The agreement addresses claims brought by 43 U.S. states and territories concerning alleged price coordination and customer allocation for certain generic medicines. Sandoz stated that its U.S. subsidiary will make the payments without any admission of wrongdoing.

The payment structure is divided into two parts:

• A primary payment of $400 million will be paid in installments over seven years, with payments scheduled to begin in 2027.
• An additional payment of approximately $50 million will be made to states that had previously reached separate settlement agreements.

Financial Impact and Outlook

Ad

Crucially for investors, Sandoz announced that the settlement does not alter its full-year 2026 guidance or its mid-term financial outlook. This suggests the company had adequately provisioned for the legal costs or that the extended payment schedule mitigates the immediate financial impact.

By resolving this long-running case, Sandoz removes a major legal overhang that has been a point of concern for the market. The settlement provides greater clarity on the company's future liabilities related to this matter.

Broader Industry Context

The litigation against Sandoz is part of a much broader, years-long legal campaign by U.S. state attorneys general. The investigation has targeted multiple generic drug manufacturers over allegations that they systematically conspired to inflate prices and stifle competition for a range of medicines.